Search filters

Filters
Clear All

Phase

  • 1
  • 2
  • 3
  • 1
  • 3

Found 3 Retinitis Pigmentosa trials

A listing of Retinitis Pigmentosa medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 NAC Attack: Phase III  Multicenter  Randomized  Parallel  Double Masked  Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa

NAC Attack: Phase III Multicenter Randomized Parallel Double Masked Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa

18-99 years
All genders
Phase 3
Currently, this study is recruiting among patients at Penn Medicine. It is not accepting non-Penn Medicine patient participants.The objective of the study will be to evaluate the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa (RP). The study is a multi-center, randomized, placebo-controlled study where adult …
 Harnessing Hormonal Variation to Probe Neural Mechanisms of OCD and Symptom Reduction by EX/RP

Harnessing Hormonal Variation to Probe Neural Mechanisms of OCD and Symptom Reduction by EX/RP

18-45 years
All genders
Studies show that hormones affect the brain’s fear extinction network, which is relevant for therapy involving exposure and ritual prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the …

UPCC 28822: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)

99 years and younger
All genders
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic BRCA1/2 gene mutation. We would like …